Synexus Clinical Research PLC
06 June 2006
Synexus Clinical Research Plc ("the Company")
Directorate change
Synexus Clinical Research Plc is pleased to announce the appointment of Malcolm
Hughes (aged 52) as Non-Executive Director with immediate effect.
Malcolm is currently Chief Executive of Greenman Group plc ("Greenman"), a
private industrial company which supplies printer cartridges to European office
supplies distributors from its manufacturing base in Bulgaria. Prior to
Greenman, he was Chief Executive of Oasis Healthcare Plc for four years during
which Oasis grew from a small regional business to become the leading dental
practice owner/operator in the UK with turnover of over £70m. His previous
experience includes senior management roles at Chloride Group plc, Ladbroke
Group plc and Management Consulting Group plc.
Commenting on the appointment, Michael Fort, chief executive of Synexus said :
" I am delighted to welcome Malcolm to the Synexus board. He brings with him
considerable knowledge and expertise, not only within the healthcare industry
but also particular experience of business operations within the emerging
economies of Eastern Europe where Synexus has established a foothold and from
which we aim to expand rapidly. We look forward to benefiting from his
contribution to the development and implementation of our growth strategy."
Malcolm Hughes commented:
"I am delighted to be joining Synexus at a time when it is seeking to build on
its recent AIM flotation through expansion of its operations in the UK and
internationally. Its unique business model offers a strong proposition to global
pharmaceutical companies as they aim to develop more cost-effective methods of
trialling new drug treatments."
Additional Information
The following is a complete list of Mr Hughes' directorships as required under
Schedule 2(g) of the AIM Rules:
Current Previous in last 5 years
Greenman Group plc Oasis Healthcare Plc
Greenman UK Limited Oasis Dental Care Limited
Greenman Europe BV The Dencare Management Group Limited
K2 Supplies Limited Dencare Management Limited
Paprika Services Limited Dencare Financial Services Limited
Betforum UK Limited Dencare Developments Limited
Dencare Implant Centres Limited
Ora Dental Group Holdings Limited
Ora Dental Group Limited
Ora EBT Trustee Limited
Inhoco 978 Limited
Inhoco 979 Limited
There is no further information required to be disclosed under Schedule 2(g) of
the AIM Rules.
For further information:
Michael Fort, Chief Executive, Synexus Clinical Research PLC 01257 230 723
Zoe Biddick, Biddicks 020 7448 1000
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.